| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 7.07▲ | 7.07▲ | 5.34▲ | 2.02▲ | 2.02▲ |
| MA10 | 3.66▲ | 3.66▲ | 2.79▲ | 1.16▲ | 1.11▲ |
| MA20 | 1.95▲ | 1.95▲ | 1.52▲ | 0.71▲ | 0.73▲ |
| MA50 | 0.92▲ | 0.95▲ | 0.79▲ | 0.41▲ | 0.99▲ |
| MA100 | 0.58▲ | 0.62▲ | 0.53▲ | 0.39▲ | 1.08▲ |
| MA200 | 0.44▲ | 0.44▲ | 0.39▲ | 0.98▲ | 6.52▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 1.061▲ | 1.064▲ | 1.020▲ | 0.554▲ | 0.596▲ |
| RSI | 99.802▲ | 99.543▲ | 99.249▲ | 98.032▲ | 92.663▲ |
| STOCH | 66.648 | 93.625▲ | 81.121▲ | 58.511 | 44.650 |
| WILL %R | -0.114▲ | -0.114▲ | -0.114▲ | -0.113▲ | -0.113▲ |
| CCI | 121.066▲ | 121.064▲ | 162.055▲ | 466.667▲ | 466.667▲ |
| ▲ PSAR&MOM | $APVO PSAR Switch Up + Momentum | Set Alert |
| ▲ RSI&MACD | $APVO MACD cross and RSI above 55 | Set Alert |
| ▲ RSI | $APVO RSI(14) Crossed Above 70 | Set Alert |
| RSI | $APVO RSI(14) Crossed Above 50 | Set Alert |
| ▲ MACD | $APVO MACD(12,26,9) Crossed Above Signal Line | Set Alert |
| MA | $APVO Price Crossed Above MA(200) | Set Alert |
| MA | $APVO Price Crossed Above MA(26) | Set Alert |
| MA | $APVO Price Crossed Above MA(13) | Set Alert |
| MA | $APVO Price Crossed Above MA(7) | Set Alert |
| ▲ GAP | $APVO Open Gap Up %5 | Set Alert |
| ▲ GAP | $APVO Open Gap Up %3 | Set Alert |
| ▲ GAP | $APVO Open Gap Up %2 | Set Alert |
| ▲ BREAK | $APVO Price Breaks 60 Days High | Set Alert |
| ▲ BREAK | $APVO Price Breaks 30 Days High | Set Alert |
| ▲ BREAK | $APVO Price Breaks 20 Days High | Set Alert |
| ▲ BREAK | $APVO Price Breaks 10 Days High | Set Alert |
|
Wednesday, December 04, 2024 05:35 AM
FLEX®platform, antibody innovation targeting difficult-to-treat cancers SEATTLE, WA / ACCESSWIRE / December 4, 2024 / Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused ...
|
|
Sunday, December 01, 2024 10:04 PM
StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a report issued on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.
|
|
Sunday, December 01, 2024 10:04 PM
StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a report issued on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 04/12/24 | 8.21 | 9.02 | 8.21 | 9.01 | 100,796 |
| 03/12/24 | 0.241 | 0.2465 | 0.23 | 0.235 | 1,792,271 |
| 02/12/24 | 0.28 | 0.28 | 0.221 | 0.2374 | 3,803,678 |
| 29/11/24 | 0.3356 | 0.3453 | 0.28 | 0.2801 | 2,663,165 |
| 27/11/24 | 0.3333 | 0.3527 | 0.3064 | 0.3453 | 1,643,428 |
| 26/11/24 | 0.31 | 0.3592 | 0.31 | 0.336 | 3,027,956 |
| 25/11/24 | 0.32 | 0.3298 | 0.30 | 0.3077 | 1,402,651 |
| 22/11/24 | 0.2819 | 0.313 | 0.2544 | 0.3077 | 2,092,098 |
| 21/11/24 | 0.2836 | 0.2898 | 0.26 | 0.2668 | 1,645,483 |
| 20/11/24 | 0.264 | 0.3255 | 0.2243 | 0.29 | 12,825,499 |
|
|
||||
|
|
||||
|
|